Animal Models of Mucositis: Implications for Therapy

Journal of Supportive Oncology

Volumn 9, Issue 5, 2011, Pages 161-168

  Bowen, Joanne M ^a   Gibson, Rachel J ^a   Keefe, Dorothy M K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; FLUOROURACIL; GLUTAMINE; GOLOTIMOD; INTERLEUKIN 11; INTESTINAL TREFOIL FACTOR; IRINOTECAN; ISEGANAN; LAPATINIB; METHOTREXATE; PALIFERMIN; PROBIOTIC AGENT; SODIUM SELENITE; VELAFERMIN;

CAUSAL ATTRIBUTION; DISEASE SEVERITY; DRUG RESPONSE; EXPERIMENTAL MODEL; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; MUCOSA INFLAMMATION; NONHUMAN; ORAL MUCOSAL DISEASE; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY; REVIEW; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MOUTH MUCOSA; MUCOSITIS; RADIOTHERAPY;

EID: 82855163917     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.04.009     Document Type: Review

References (118)

1. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 2004, 4(6):277-284.
2. Keefe D.M. Mucositis guidelines: what have they achieved, and where to from here?. Support Care Cancer 2006, 14(6):489-491.
3. Keefe D.M., Peterson D.E., Schubert M.M. Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls. Support Care Cancer 2006, 14:492-498.
4. Elting L.S., Cooksley C., Chambers M., Cantor S.B., Manzullo E., Rubenstein E.B. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003, 98(7):1531-1539.
5. Savarese D.M., Hsieh C., Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997, 15(8):2981-2995.
6. Elting L.S., Cooksley C.D., Chambers M.S., Garden A.S. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007, 68(4):1110-1120.
7. Keefe D.M. Gastrointestinal mucositis: a new biological model. Support Care Cancer 2004, 12(1):6-9.
8. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., Bekele B.N., Raber-Durlacher J., Donnelly J.P., Rubenstein E.B. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004, 100(suppl 9):1995-2025. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology.
9. Dorr W., Brankovic K., Hartmann B. Repopulation in mouse oral mucosa: changes in the effect of dose fractionation. Int J Radiat Biol 2000, 76(3):383-390.
10. Dorr W., Hamilton C.S., Boyd T., Reed B., Denham J.W. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002, 52(4):911-917.
11. Dorr W., Spekl K., Farrell C.L. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 2002, 35(suppl 1):86-92.
12. Dorr W., Spekl K., Farrell C.L. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002, 54(1):245-251.
13. Dorr W., Spekl K., Martin M. Radiation-induced mucositis in mice: strain differences. Cell Prolif 2002, 35(suppl 1):60-67.
14. Dorr W., Kummermehr J. Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother Oncol 1990, 17(3):249-259.
15. Kilic Y., Rajewski K., Dorr W. Effect of post-exposure administration of keratinocyte growth factor (palifermin) on radiation effects in oral mucosa in mice. Radiat Environ Biophys 2007, 46(1):13-19.
16. Haagen J., Krohn H., Rollig S., Schmidt M., Wolfram K., Dorr W. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009, 92(3):472-476.
17. Jaal J., Richter C., Dorr W. Effect of recombinant human keratinocyte growth factor (δ23rHuKGF, palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation. Int J Radiat Biol 2010, 86(10):860-866.
18. Dorr W., Bassler S., Reichel S., Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 2005, 62(3):881-887.
19. Dorr W., Heider K., Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol 2005, 81(8):557-565.
20. Dorr W., Noack R., Spekl K., Farrell C.L. Amelioration of radiation-induced oral mucositis by keratinocyte growth factor (rhKGF): experimental studies. Int J Radiat Oncol Biol Phys 2000, 46:729.
21. Dorr W., Noack R., Spekl K., Farrell C.L. Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 2001, 77(3):341-347.
22. Dorr W., Reichel S., Spekl K. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 2005, 75(1):99-105.
23. Dorr W., Spekl K., Farrell C.L. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002, 54(1):245-251.
24. Gehrisch A., Dorr W. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol 2007, 183(1):36-42.
25. Fleischer G., Dorr W. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine. Strahlenther Onkol 2006, 182(10):567-575.
26. Fehrmann A., Dorr W. Effect of EGFR-inhibition on the radiation response of oral mucosa: experimental studies in mouse tongue epithelium. Int J Radiat Biol 2005, 81(6):437-443.
27. Dorr W., Hirler E., Honig M. Response of mouse tongue epithelium to single doses of bleomycin and radiation. Radiother Oncol 1993, 27(3):237-244.
28. Dorr W., Schlichting S., Bray M.A., Flockhart I.R., Hopewell J.W. Effects of dexpanthenol with or without aloe vera extract on radiation-induced oral mucositis: preclinical studies. Int J Radiat Biol 2005, 81(3):243-250.
29. Pabst S., Spekl K., Dorr W. Changes in the effect of dose fractionation during daily fractionated irradiation: studies in mouse oral mucosa. Int J Radiat Oncol Biol Phys 2004, 58(2):485-492.
30. Sonis S.T., Tracey C., Shklar G., Jenson J., Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990, 69(4):437-443.
31. Sonis S.T. A biological approach to mucositis. J Support Oncol 2004, 2(1):21-32.
32. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 2004, 4(4):277-284.
33. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 2004, 20(1):11-15.
34. Caluwaerts S., Vandenbroucke K., Steidler L., Neirynck S., Vanhoenacker P., Corveleyn S., Watkins B., Sonis S., Coulie B., Rottiers P. AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 2010, 46(7):564-570.
35. Hwang D., Popat R., Bragdon C., O'Donnell K.E., Sonis S.T. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 100(3):321-329.
36. Murphy C.K., Fey E.G., Watkins B.A., Wong V., Rothstein D., Sonis S.T. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res 2008, 14(13):4292-4297.
37. Murray L.A., Kramer M.S., Hesson D.P., Watkins B.A., Fey E.G., Argentieri R.L., Shaheen F., Knight D.A., Sonis S.T. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 2010, 3:11.
38. Ara G., Watkins B.A., Zhong H., Hawthorne T.R., Karkaria C.E., Sonis S.T., Larochelle W.J. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol 2008, 84(5):401-412.
39. Watkins B., Pouliot K., Fey E., Tuthill C., Sonis S. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07). Oral Dis 2010, 16(7):655-660.
40. Alvarez E., Fey E.G., Valax P., Yim Z., Peterson J.D., Mesri M., Jeffers M., Dindinger M., Twomlow N., Ghatpande A., LaRochelle W.J., Sonis S.T., Lichenstein H.S. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 2003, 9(9):3454-3461.
41. Sonis S.T., Costa J.W., Evitts S.M., Lindquist L.E., Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992, 74(6):749-755.
42. Sonis S.T., Van Vugt A.G., Brien J.P., Muska A.D., Bruskin A.M., Rose A., Haley J.D. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997, 33(1):47-54.
43. Sonis S.T., Van Vugt A.G., McDonald J., Dotoli E., Schwertschlag U., Szklut P., Keith J. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997, 9(8):605-612.
44. Sonis S.T., Peterson R.L., Edwards L.J., Lucey C.A., Wang L., Mason L., Login G., Ymamkawa M., Moses G., Bouchard P., Hayes L.L., Bedrosian C., Dorner A.J. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000, 36(4):373-381.
45. Loury D., Embree J.R., Steinberg D.A., Sonis S.T., Fiddes J.C. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 87(5):544-551.
46. Keefe D.M.K. The effect of cytotoxic chemotherapy on the mucosa of the small intestine 1998, PhD diss. University of Adelaide.
47. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47(5):632-637.
48. Gibson R.J., Bowen J.M., Keefe D.M. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005, 116(3):464-470.
49. Gibson R.J., Keefe D.M., Clarke J.M., Regester G.O., Thompson F.M., Goland G.J., Edwards B.G., Cummins A.G. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002, 50(1):53-58.
50. Gibson R.J., Stringer A.M., Bowen J.M., Logan R.M., Yeoh A.S., Burns J., Alvarez E., Keefe D.M. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007, 6(4):541-547.
51. Bowen J.M., Stringer A.M., Gibson R.J., Yeoh A.S., Hannam S., Keefe D.M. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007, 6(9):1449-1454.
52. Gibson R.J., Keefe D.M.K., Thompson F.M., Clarke J.M., Goland G.J., Cummins A.G. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002, 47(12):2751-2757.
53. Gibson R.J., Bowen J.M., Cummins A.G., Keefe D.M. Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 2005, 4(4):188-195.
54. Bowen J.M., Gibson R.J., Keefe D.M., Cummins A.G. Cytotoxic chemotherapy upregulate pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005, 37(1):56-62.
55. Gibson R.J., Bowen J.M., Inglis M.R., Cummins A.G., Keefe D.M. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003, 18(9):1095-1100.
56. Bowen J.M., Gibson R.J., Stringer A.M., Chan T.W., Prabowo A.S., Cummins A.G., Keefe D.M. Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs 2007, 18(2):197-210.
57. Bowen J.M., Gibson R.J., Tsykin A., Stringer A.M., Logan R.M., Keefe D.M. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 2007, 121(8):1847-1856.
58. Gibson R.J., Bowen J.M., Alvarez E., Finnie J., Keefe D.M. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007, 53(5):360-369.
59. Logan R.M., Stringer A.M., Bowen J.M., Gibson R.J., Sonis S.T., Keefe D.M. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008, 7(7):1139-1145.
60. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Laurence J., Keefe D.M. Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 2009, 64(1):123-132.
61. Bowen J.M., Tsykin A., Stringer A.M., Logan R.M., Gibson R.J., Keefe D.M. Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology 2010, 269(1):1-12.
62. Al-Dasooqi N., Gibson R.J., Bowen J.M., Logan R.M., Stringer A.M., Keefe D.M. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) 2010, 235(10):1244-1256.
63. Logan R.M., Stringer A.M., Bowen J.M., Gibson R.J., Sonis S.T., Keefe D.M. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemother Pharmacol 2009, 63(2):239-251.
64. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Hamilton J., Keefe D.M. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009, 234(4):430-441.
65. Yeoh A.S., Gibson R.J., Yeoh E.E., Bowen J.M., Stringer A.M., Giam K.A., Keefe D.M. A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther 2007, 6(8):2319-2327.
66. Howarth G., Francis G.L., Cool J.C., Xu X., Byard R.W., Read L.C. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996, 126(10):2519-2530.
67. Xian C.J., Couper R., Howarth G.S., Read L.C., Kallincos N.C. Increased expression of HGF and c-met in rat small intesitne during recovery from methotrexate-induced mucositis. Br J Cancer 2000, 82(4):945-952.
68. Xian C.J., Howarth G.S., Mardell C.E., Cool J.C., Familari M., Read L.C., Giraud A.S. Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol Gastrointest Liver Physiol 1999, 277(4 Pt 1):G785-G795.
69. Howarth G.S., Cool J.C., Bourne A.J., Ballard F.J., Read L.C. Insulin-like growth factor-I (IGF-I) stimulates regrowth of the damaged intestine in rats, when administered following, but not concurrent with, methotrexate. Growth Factors 1998, 15(4):279-292.
70. Howarth G.S., Francis G.L., Cool J.C., Xu X., Byard R.W., Read L.C. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996, 126(10):2519-2530.
71. Xian C.J., Cool J.C., Howarth G.S., Read L.C. Effects of TGF-alpha gene knockout on epithelial cell kinetics and repair of methotrexate-induced damage in mouse small intestine. J Cell Physiol 2002, 191(1):105-115.
72. Clarke J.M., Butler R., Howarth G.S., Read L.C., Regester G.O. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002, 38:478-485.
73. Tran C.D., Howarth G.S., Coyle P., Philcox J.C., Rofe A.M., Butler R.N. Dietary supplementation with zinc and a growth factor extract derived from bovine cheese whey improves methotrexate-damaged rat intestine. Am J Clin Nutr 2003, 77(5):1296-1303.
74. Lindsay R.J., Geier M.S., Yazbeck R., Butler R.N., Howarth G.S. Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr 2010, 104(4):513-519.
75. Howarth G.S., Fraser R., Frisby C.L., Schirmer M.B., Yeoh E.K. Effects of insulin-like growth factor-I administration on radiation enteritis in rats. Scand J Gastroenterol 1997, 32(11):1118-1124.
76. Fraser R., Frisby C., Blackshaw L.A., Schirmer M., Howarth G., Yeoh E. Small intestinal dysmotility following abdominal irradiation in the rat small intestine. Neurogastroenterol Motil 1998, 10(5):413-419.
77. Fraser R., Frisby C., Schirmer M., Blackshaw L.A., Langman J., Howarth G., Yeoh E.K. Divergence of mucosal and motor effects of insulin-like growth factor (IGF)-I and LR3IGF-I on rat isolated ileum following abdominal irradiation. J Gastroenterol Hepatol 2000, 15(10):1132-1137.
78. Kushwaha R.S., Hayne D., Vaizey C.J., Wrightham E., Payne H., Boulos P.B. Physiologic changes of the anorectum after pelvic radiotherapy for the treatment of prostate and bladder cancer. Dis Colon Rectum 2003, 46(9):1182-1188.
79. Yeoh E.K., Russo A., Botten R., Fraser R., Roos D., Penniment M., Borg M., Sun W.M. Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function. Gut 1998, 43(1):123-127.
80. Withers H.R., Elkind M.M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 1970, 17(3):261-267.
81. Potten C.S., Rezvani M., Hendry J.H., Moore J.V., Major D. The correction of intestinal microcolony counts for variation in size. Int J Radiat Biol Relat Stud Phys Chem Med 1981, 40(3):321-326.
82. Hendry J.H., Potten C.S., Roberts N.P. The gastrointestinal syndrome and mucosal clonogenic cells: relationships between target cell sensitivities, LD50 and cell survival, and their modification by antibiotics. Radiat Res 1983, 96(1):100-112.
83. Ijiri K., Potten C.S. Circadian rhythms in the incidence of apoptotic cells and number of clonogenic cells in intestinal crypts after radiation using normal and reversed light conditions. Int J Radiat Biol Relat Stud Phys Chem Med 1988, 53(5):717-727.
84. Shukla P., Gupta D., Bisht S.S., Pant M.C., Bhatt M.L., Gupta R., Srivastava K., Gupta S., Dhawan A., Mishra D., Negi M.P. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. Cancer 2010, 116(8):2031-2035.
85. Farrell C.L., Bready J.V., Rex K.L., Chen J.N., DiPalma C.R., Whitcomb K.L., Yin S., Hill D.C., Wiemann B., Starnes C.O., Havill A.M., Lu Z.N., Aukerman S.L., Pierce G.F., Thomason A., Potten C.S., Ulich T.R., Lacey D.L. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998, 58(5):933-939.
86. Booth D., Haley J.D., Bruskin A.M., Potten C.S. Transforming growth factor-β3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling. Int J Cancer 2000, 86(1):53-59.
87. Potten C.S., Booth D., Haley J.D. Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo. Br J Cancer 1997, 75(10):1454-1459.
88. Potten C.S. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995, 62(3):356-361.
89. Potten C.S. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 1996, 14(4):452-459.
90. Booth C., Booth D., Williamson S., Demchyshyn L.L., Potten C.S. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004, 37(6):385-400.
91. Hauer-Jensen M., Poulakos L., Osborne J.W. Effects of accelerated fractionation on radiation injury of the small intestine: a new rat model. Int J Radiat Oncol Biol Phys 1988, 14(6):1205-1212.
92. Hauer-Jensen M. Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol 1990, 29(4):401-415.
93. Richter K.K., Wang J., Fagerhol M.K., Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001, 59(1):81-85.
94. Langberg C.W., Hauer-Jensen M. Influence of fraction size on the development of late radiation enteropathy. An experimental study in the rat. Acta Oncol 1996, 35(1):89-94.
95. Bowen J, Darby J, Plews E, Stringer A, Keefe D. Characterisation of EGF receptor tyrosine kinase inhibitor-induced diarrhoea. Supportive Care in Cancer, 18 (suppl 3). 107 [abstract #167].
96. Dorr W., Spekl K., Farrell C.L. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 2002, 35(suppl 1):86-92.
97. Meropol N.J., Somer R.A., Gutheil J., Pelley R.J., Modiano M.R., Rowinsky E.K., Rothenberg M.L., Redding S.W., Serdar C.M., Yao B., Heard R., Rosen L.S. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003, 21(8):1452-1458.
98. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., Shea T., Yanovich S., Hansen K., Noga S., McCarty J., LeMaistre C.F., Sung E.C., Blazar B.R., Elhardt D., Chen M.G., Emmanouilides C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351(25):2590-2598.
99. Brizel D.M., Murphy B.A., Rosenthal D.I., Pandya K.J., Glück S., Brizel H.E., Meredith R.F., Berger D., Chen M.G., Mendenhall W. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008, 26(15):2489-2496.
100. Vadhan-Raj S., Trent J., Patel S., Zhou X., Johnson M.M., Araujo D., Ludwig J.A., O'Roark S., Gillenwater A.M., Bueso-Ramos C., El-Naggar A.K., Benjamin R.S. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 2010, 153(6):358-367.
101. Delia P., Sansotta G., Donato V., Messina G., Frosina P., Pergolizzi S., De Renzis c., Famularo G. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002, 97(8):2150-2152.
102. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y., Moore J.O., Gordon M.S., Kuca B., Beach K.J., Loewy J.W., Garnick M.B., Kaye J.A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87(9):3607-3614.
103. Schubert M.M., Eduardo F.P., Guthrie K.A., Franquin J.C., Bensadoun R.J., Migliorati C.A., Lloid C.M., Eduardo C.P., Walter N.F., Marques M.M., Hamdi M. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficiacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007, 15(10):1145-1154.
104. Zanin T., Zanin F., Carvalhosa A.A., Castro P.H., Pacheco M.T., Zanin I.C., Brugnera A. Use of 660-nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy. Photomed Laser Surg 2010, 28(2):233-237.
105. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 2002, 29(suppl 19):80-83.
106. Law A., Kennedy T., Pellitteri P., Wood C., Christie D., Yumen O. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007, 69(5):1361-1368.
107. Klimberg V.S., Nwokedi E., Hutchins L.F., Pappas A.A., Lang N.P., Broadwater J.R., Read R.C., Westbrook K.C. Glutamine facilitates chemotherapy while reducing toxicity. JPEN J Parenter Enteral Nutr 1992, 16(suppl 6):83S-87S.
108. Rubio I.T., Cao Y., Hutchins L.F., Westbrook K.C., Klimberg V.S. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 1998, 227(5):772-778.
109. Vera G., Chiarlone A., Martin M.I., Abalo R. Altered feeding behaviour induced by long-term cisplatin in rats. Auton Neurosci 2006, 126-127:81-92.
110. Ijiri K., Potten C.S. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983, 47(2):175-185.
111. Ijiri K., Potten C.S. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 1987, 55(2):113-123.
112. Sonis S., Haddad R., Posner M., Watkins B., Fey E., Morgan T.V., Mookanamparambil L., Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007, 43(3):289-300.
113. Nadler L.M., Stashenko P., Hardy R., Kaplan W.D., Button L.N., Kufe D.W., Antman K.H., Schlossman S.F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40(9):3147-3154.
114. Bert B., Fink H., Sohr R., Rex A. Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacol Biochem Behav 2001, 70(2-3):411-420.
115. Staack R.F., Paul L.D., Springer D., Kraemer T., Maurer H.H. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and dark agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004, 67(2):235-244.
116. Kawase A., Fujii A., Negoro M., Akai R., Ishikubo M., Komura H., Iwaki M. Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. Drug Metab Pharmacokinet 2008, 23(3):196-206.
117. Martignoni M., Groothuis G.M., de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006, 2(6):875-894.
118. Sikora K. The impact of future technology on cancer care. Clin Med 2002, 2(6):560-568.